The novel thioredoxin reductase inhibitor A-Z2 triggers intrinsic apoptosis and shows efficacy in the treatment of acute myeloid leukemia
作者:Dongdong Zhang、Yujiao Liu、Ziyi Luo、Yanling Chen、Anjie Xu、Yuxing Liang、Balu Wu、Xiqin Tong、Xiaoyan Liu、Hui Shen、Li Liu、Yongchang Wei、Haibing Zhou、Yi Liu、Fuling Zhou
DOI:10.1016/j.freeradbiomed.2019.11.013
日期:2020.1
as a promising approach to treating AML. Both arsenicals and azelaic acid (AZA) are thioredoxin reductase (TrxR) inhibitors and possess antileukemic effects. In this study, to exploit agents with higher potency and lower toxicity, we got some organic arsenicals and further synthesized a series of targeted compounds by binding AZA to organic arsenicals, and then screened the most effective one, N-(4-(1
急性髓细胞性白血病(AML)患者的化学耐药性和高复发率与硫氧还蛋白(Trx)的过表达有关。因此,以Trx系统为目标已成为治疗AML的一种有前途的方法。砷和壬二酸(AZA)都是硫氧还蛋白还原酶(TrxR)抑制剂,并具有抗白血病作用。在这项研究中,为了开发具有更高效力和更低毒性的药物,我们获得了一些有机砷,并通过将AZA与有机砷结合而进一步合成了一系列目标化合物,然后筛选出最有效的N-(4-(1, 3,2-二硫杂萘烷-2-基)苯基)-壬二酰胺(A-Z2)。与AZA或砷剂相比,A-Z2对TrxR活性和AML细胞系具有更强的抑制作用。此外,与传统的化学治疗药物相比,A-Z2对健康细胞的毒性较小。A-Z2通过折叠线粒体膜电位,降低ATP水平,释放细胞色素c和TNF-α,激活caspase 9、8和3诱导凋亡。机理分析表明,A-Z2通过直接激活内在的凋亡途径。选择性靶向TrxR / Trx并间接抑制N